These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. How to Position Pasireotide LAR Treatment in Acromegaly. Coopmans EC; Muhammad A; van der Lely AJ; Janssen JAMJL; Neggers SJCMM J Clin Endocrinol Metab; 2019 Jun; 104(6):1978-1988. PubMed ID: 30608534 [TBL] [Abstract][Full Text] [Related]
3. Current and future medical treatments for patients with acromegaly. Maffezzoni F; Formenti AM; Mazziotti G; Frara S; Giustina A Expert Opin Pharmacother; 2016 Aug; 17(12):1631-42. PubMed ID: 27352098 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain. Peral C; Cordido F; Gimeno-Ballester V; Mir N; Sánchez-Cenizo L; Rubio-Rodríguez D; Rubio-Terrés C Expert Rev Pharmacoecon Outcomes Res; 2020 Feb; 20(1):105-114. PubMed ID: 31055976 [No Abstract] [Full Text] [Related]
5. Combined treatment of somatostatin analogues with pegvisomant in acromegaly. Franck SE; Muhammad A; van der Lely AJ; Neggers SJ Endocrine; 2016 May; 52(2):206-13. PubMed ID: 26661938 [TBL] [Abstract][Full Text] [Related]
6. Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second-Line Therapies: A Longitudinal Study. Chiloiro S; Bima C; Tartaglione T; Giampietro A; Gessi M; Lauretti L; Anile C; Colosimo C; Rindi G; Pontecorvi A; De Marinis L; Bianchi A J Clin Endocrinol Metab; 2019 Nov; 104(11):5478-5482. PubMed ID: 31219586 [TBL] [Abstract][Full Text] [Related]
8. Diagnosis, treatment and follow-up of patients with acromegaly in a clinical practice setting in Spain: the ACROPRAXIS program Delphi survey. de Pablos-Velasco P; Venegas EM; Álvarez Escolá C; Fajardo C; de Miguel P; González N; Bernabéu I; Valdés N; Paja M; Díez JJ; Biagetti B Pituitary; 2020 Apr; 23(2):129-139. PubMed ID: 31823249 [TBL] [Abstract][Full Text] [Related]
9. Insights from an Italian Delphi panel: exploring resistance to first-generation somatostatin receptor ligands and guiding second-line medical therapies in acromegaly management. Grottoli S; Maffei P; Tresoldi AS; Granato S; Benedan L; Mariani P; Giustina A J Endocrinol Invest; 2024 May; ():. PubMed ID: 38809458 [TBL] [Abstract][Full Text] [Related]
10. Current therapy and drug pipeline for the treatment of patients with acromegaly. Kumar SS; Ayuk J; Murray RD Adv Ther; 2009 Apr; 26(4):383-403. PubMed ID: 19444656 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study. Shimon I; Adnan Z; Gorshtein A; Baraf L; Saba Khazen N; Gershinsky M; Pauker Y; Abid A; Niven MJ; Shechner C; Greenman Y Endocrine; 2018 Nov; 62(2):448-455. PubMed ID: 30051198 [TBL] [Abstract][Full Text] [Related]
12. Somatostatin analog and pegvisomant combination therapy for acromegaly. Neggers SJ; van der Lely AJ Nat Rev Endocrinol; 2009 Oct; 5(10):546-52. PubMed ID: 19763127 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report. Ciresi A; Radellini S; Guarnotta V; Giordano C BMC Endocr Disord; 2018 Jan; 18(1):2. PubMed ID: 29361932 [TBL] [Abstract][Full Text] [Related]
14. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study. Puig-Domingo M; Soto A; Venegas E; Vilchez R; Blanco C; Cordido F; Lucas T; Marazuela M; Casany R; Cuatrecasas G; Fajardo C; Gálvez MÁ; Maraver S; Martín T; Romero E; Paja M; Picó A; Bernabeu I; Resmini E; Endocrinol Nutr; 2016 Oct; 63(8):397-408. PubMed ID: 27448708 [TBL] [Abstract][Full Text] [Related]
16. Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance. Yamaguchi H; Shimatsu A; Okayama A; Sato T Endocr J; 2020 Feb; 67(2):201-210. PubMed ID: 31723069 [TBL] [Abstract][Full Text] [Related]
17. Review of current and emerging treatment options in acromegaly. Muhammad A; van der Lely AJ; Neggers SJ Neth J Med; 2015 Oct; 73(8):362-7. PubMed ID: 26478545 [TBL] [Abstract][Full Text] [Related]
18. Current pharmacotherapy for acromegaly: a review. Biermasz NR; Romijn JA; Pereira AM; Roelfsema F Expert Opin Pharmacother; 2005 Nov; 6(14):2393-405. PubMed ID: 16259571 [TBL] [Abstract][Full Text] [Related]
19. Acromegaly. Scacchi M; Cavagnini F Pituitary; 2006; 9(4):297-303. PubMed ID: 17077948 [TBL] [Abstract][Full Text] [Related]
20. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly. Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]